Bicara Therapeutics Inc (BCAX)
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is designed as a bifunctional antibody that brings together an epidermal growth factor receptor-directed monoclonal antibody with human transforming growth factor beta activity for use in solid tumor treatment. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics common stock is listed on the NASDAQ under the symbol BCAX.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BCAX
|
$19.80
|
-28.2% Downside
|
Overvalued
|
$31.46
|
14.1% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-11.5x
|
3.5x
|
—
|
1.784 B
|
1.278 B
|
0.1%
|
55.8%
|
26.0
|
—
|
74.1%
|
